Is an extended supraomohyoid neck dissection including level IV indicated for patients with squamous cell carcinoma of the lateral oral tongue and a clinically N0 neck, and what is the justification?

Extended Supraomohyoid Neck Dissection for Lateral Tongue SCC

For squamous cell carcinoma of the lateral oral tongue with a clinically N0 neck, the recommendation to routinely include level IV in an extended supraomohyoid neck dissection is NOT supported by current high-quality guidelines or the most recent evidence.

Guideline-Based Recommendations

The National Comprehensive Cancer Network (NCCN) establishes clear standards for selective neck dissection in oral cavity tumors:

• The minimum required extent for clinically N0 oral tongue carcinoma is levels I-III only 1
• Level IV dissection is recommended only when postoperative radiation is not planned, representing an optional extension rather than a mandatory requirement 1
• Level IV is not designated as a routinely required level for clinically N0 oral cavity disease 1

Evidence Analysis: Level IV Involvement Rates

The most recent and comprehensive evidence demonstrates extremely low rates of level IV involvement in N0 lateral tongue cancer:

Recent High-Quality Studies

• A 2025 study of 111 patients found only 6.3% occult metastasis to level IV in T1/T2 N0 oral tongue SCC 2
• A 2020 systematic review and meta-analysis of 498 patients showed level IV involvement in only 2.8% of cases 3
• No skip metastases to level IV were identified in multiple studies, indicating that level IV disease does not occur without involvement of levels I-III 4

Earlier Supporting Data

• A 2016 study found 6.25% level IV metastasis rate and concluded "there is no need for level IV lymph node dissection in a N0 patient" 5
• A 2014 study found no occult metastasis at level IV in clinically node-negative patients 4

Critical Counterpoint: The 2003 Study

One older study from 2003 reported 10% level IV involvement and advocated for extended dissection 6. However, this study:

• Predates modern imaging techniques and clinical staging accuracy
• Has been contradicted by multiple subsequent higher-quality studies with larger sample sizes
• Does not align with current guideline recommendations from major societies

Clinical Decision Algorithm

For T2N0 lateral tongue SCC, the surgical approach should be:

1. Standard approach: Ipsilateral selective neck dissection levels I-III 1

2. Consider extending to level IV if:

   • Postoperative radiation is definitively not planned 1
   • Intraoperative findings suggest higher-risk disease
   • Patient-specific factors preclude adjuvant therapy

3. Do NOT extend to level IV routinely because:

   • The risk of occult level IV disease is only 2.8-6.3% 2, 3
   • Skip metastases to level IV without upper level involvement do not occur 4
   • Postoperative radiation will adequately address the minimal risk if pathology reveals adverse features 1

Important Caveats

The 6.3% risk of level IV involvement, while low, is not zero 2. The argument for extended dissection rests on the concern that missing a positive level IV node could result in failure to administer necessary postoperative radiotherapy 2. However:

• Modern pathology-driven adjuvant therapy protocols effectively address this risk 1
• The presence of any positive nodes in levels I-III triggers appropriate adjuvant treatment 1
• The morbidity of routine level IV dissection in 93.7% of patients who don't need it outweighs the theoretical benefit 3

Morbidity and Quality of Life Considerations

Extending dissection to level IV increases operative time, risk of accessory nerve injury, and shoulder dysfunction without proven survival benefit in the vast majority of patients. Given that:

• 93.7-97.2% of patients will have no level IV disease 2, 3
• Adjuvant radiation effectively treats microscopic disease
• No survival advantage has been demonstrated for routine level IV dissection

The standard levels I-III dissection represents the optimal balance of oncologic control and functional preservation for most patients with N0 lateral tongue cancer.